ArticleCureus2026
Vasoactive Intestinal Peptide (VIP)-Secreting Neuroblastic Tumors in Children Presenting With Chronic Secretory Diarrhea: A Report of Two Cases.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasoactive intestinal peptide (VIP)-secreting neuroblastic tumors are rare pediatric neoplasms that may present with chronic secretory diarrhea prior to tumor detection, posing significant diagnostic and therapeutic challenges. VIP-induced diarrhea is typically profuse, watery, and refractory to standard management, often resulting in dehydration, electrolyte imbalance, weight loss, and failure to thrive. Herein, we report two pediatric patients with neuroblastoma who presented with chronic secretory diarrhea as the initial and predominant symptom. In both cases, the persistent diarrhea remained unexplained by common etiologies and was unresponsive to conventional therapies. After approximately three months of ongoing symptoms accompanied by progressive abdominal distension, radiologic evaluation revealed intra-abdominal masses in both cases. The diagnosis of neuroblastoma was confirmed by tumor biopsy in one patient and bone marrow biopsy in the other. Serum VIP levels were not available in either case; however, the clinical presentation was consistent with VIP-mediated secretory diarrhea. Although surgical resection of VIP-secreting neuroblastic tumors in localized disease is typically associated with resolution of diarrhea and favorable outcomes, delayed diagnosis could result in advanced, metastatic, and inoperable disease. Both of our cases had metastatic, inoperable disease at the time of diagnosis, and proved fatal in one. These cases underscore the importance of considering VIP-secreting neuroblastic tumors in the differential diagnosis of children presenting with unexplained, treatment-resistant secretory diarrhea. Early recognition may facilitate timely diagnosis and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.